The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CRDF | -40.64% | -86.94% | -33.44% | -100% |
| S&P | +18.54% | +92.9% | +14.04% | +519% |
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
These clinical-stage biotech stocks are headed in opposite directions today.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.12M | -25.8% |
| Gross Profit | -$0.11M | -286.2% |
| Gross Margin | -89.26% | -124.8% |
| Market Cap | $209.56M | 111.1% |
| Market Cap / Employee | $6.35M | 0.0% |
| Employees | 33 | 3.1% |
| Net Income | -$13.94M | -18.4% |
| EBITDA | -$14.55M | -16.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.78M | -57.7% |
| Accounts Receivable | $0.53M | 16.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.46M | -59.3% |
| Short Term Debt | $0.72M | 2.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -71.96% | -22.0% |
| Return On Invested Capital | -36.55% | 25.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8.35M | 9.5% |
| Operating Free Cash Flow | -$8.33M | 9.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.63 | 4.28 | 2.52 | 2.96 | 81.39% |
| Price to Sales | 181.61 | 350.52 | 355.25 | 383.80 | 156.48% |
| Price to Tangible Book Value | 2.63 | 4.28 | 2.52 | 2.96 | 81.39% |
| Enterprise Value to EBITDA | -5.53 | -11.99 | -9.21 | -9.61 | 191.28% |
| Return on Equity | -67.6% | -59.5% | -74.2% | -91.9% | 56.34% |
| Total Debt | $1.69M | $1.52M | $1.36M | $1.19M | -35.70% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
